Emory University Winship Cancer Institute, Atlanta
Liberty County Cancer Care, Hinesville
Pembroke Medical Oncology & St Joseph's/Candler Oncology Infusion Suite, Pembroke
e altri 2

In reclutamentoFase 3

Età 60 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06377852

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Clinical Trial Site, Marietta

In reclutamentoFase 3

Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07085767

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Piedmont Columbus Regional - John B. Amos Cancer Center, Columbus
Central Georgia Cancer Care, Macon
City of Hope National Medical Center, Atlanta Cancer Center, Newnan
e altri 2

In reclutamentoFase 3

Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07174336

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Emory University School of Medicine - Winship Cancer Institute, Atlanta

In reclutamentoFase 1

Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07114601

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Winship Cancer Institute, Atlanta

In reclutamentoFase 2

Età 18 e oltre · Donne · Aggiornato il 22 set 2026 · NCT07287098

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

University Cancer & Blood Center, LLC, Athens
Winship Cancer Institute of Emory University, Atlanta

In reclutamentoFase 1/2

Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT06827236

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

University Blood & Cancer Center, LLC, Athens
Winship Cancer Institute, Atlanta
Northside Hospital, Atlanta

In reclutamentoFase 3

Età 18 e oltre · Tutti i sessi · Aggiornato il 15 set 2026 · NCT06492616

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Georgia Cancer Center at Augusta University, Augusta

In reclutamentoFase 1

Età 18 e oltre · Tutti i sessi · Aggiornato il 10 set 2026 · NCT06293898

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

Emory University (Data Collection Only), Atlanta

In reclutamentoFase 2

Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT05570253

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

University Cancer & Blood Center, LLC, Athens
Summit Cancer Care, Savannah

In reclutamentoFase 1

Età da 18 a 55 · Donne · Aggiornato il 9 set 2026 · NCT07310420

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

Research Site, Marietta

In reclutamentoFase 3

Età da 18 a 130 · Tutti i sessi · Aggiornato il 8 set 2026 · NCT07647328

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Winship Cancer Institute of Emory University, Atlanta

In reclutamentoFase 1/2

Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT07100106

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

Emory University, Atlanta

In reclutamentoFase 1

Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT06400472

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Atlanta Cancer Care - Northside Hospital, Atlanta

In reclutamentoFase 3

Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT06982521

Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

Emory University, Atlanta

In reclutamentoFase 2

Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT05846789

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Northwest Georgia Oncology Centers PC - Marietta, Marietta

In reclutamentoFase 3

Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT06790693

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Phoebe Putney Memorial Hospital, Albany
University Cancer and Blood Center LLC, Athens
Grady Health System, Atlanta
e altri 16

In reclutamentoFase 3

Età da 18 a 60 · Donne · Aggiornato il 2 set 2026 · NCT05879926

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Winship Cancer Institute of Emory University, Atlanta

In reclutamentoFase 3

Età 18 e oltre · Tutti i sessi · Aggiornato il 2 set 2026 · NCT06072612

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

Emory University - Winship Cancer Institute, Atlanta

In reclutamentoFase 1

Età 18 e oltre · Tutti i sessi · Aggiornato il 27 ago 2026 · NCT06582017

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

Augusta University, Augusta

In reclutamentoFase 2

Età 18 e oltre · Tutti i sessi · Aggiornato il 21 ago 2026 · NCT06764940

Mobile Health Patient Navigation for the Improvement of Screening and the Early Detection of Breast Cancer in Women Accessing Primary Care Clinics in Kenya

Emory University Hospital/Winship Cancer Institute, Atlanta

In reclutamentoVolontari sani benvenuti

Età 18 e oltre · Tutti i sessi · Aggiornato il 14 ago 2026 · NCT07764796

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

Winship Cancer Institute at Emory University, Atlanta

In reclutamentoFase 2

Età 18 e oltre · Tutti i sessi · Aggiornato il 12 ago 2026 · NCT06263543

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Emory University, Atlanta

In reclutamentoFase 1

Età 18 e oltre · Tutti i sessi · Aggiornato il 12 ago 2026 · NCT05304962

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Northside Hospital, Atlanta

In reclutamentoFase 2/3

Età 18 e oltre · Tutti i sessi · Aggiornato il 10 ago 2026 · NCT06926868

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

City of Hope - Cancer Center Atlanta, Newnan

In reclutamentoFase 3

Età da 18 a 100 · Tutti i sessi · Aggiornato il 6 ago 2026 · NCT05232916

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Augusta University Georgia Cancer Center, Augusta

In reclutamentoFase 1/2

Età 18 e oltre · Tutti i sessi · Aggiornato il 4 ago 2026 · NCT05579366

E-Mindfulness Approaches for Living After Breast Cancer

Grady Health System, Atlanta
Emory University Hospital Midtown, Atlanta
Emory University Hospital/Winship Cancer Institute, Atlanta
e altri 3

In reclutamentoFase 3

Età da 18 a 50 · Tutti i sessi · Aggiornato il 4 ago 2026 · NCT06748222

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Emory University, Atlanta

In reclutamentoFase 1/2

Età 18 e oltre · Tutti i sessi · Aggiornato il 30 lug 2026 · NCT07288359

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Winship Cancer Institute, Emory University, Atlanta

In reclutamentoFase 1/2

Età 18 e oltre · Tutti i sessi · Aggiornato il 7 lug 2026 · NCT05768139

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

Winship Cancer Institute, Emory University, Atlanta

In reclutamentoFase 1/2

Età 18 e oltre · Tutti i sessi · Aggiornato il 29 giu 2026 · NCT05377996

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

GSK Investigational Site, Atlanta

In reclutamentoFase 2

Età 18 e oltre · Tutti i sessi · Aggiornato il 24 giu 2026 · NCT04641247

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Emory University School of Medicine, Atlanta

In reclutamentoFase 3

Età 18 e oltre · Tutti i sessi · Aggiornato il 22 giu 2026 · NCT05696626

Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics

Emory University Hospital/Winship Cancer Institute, Atlanta

In reclutamentoVolontari sani benvenuti

Età 25 e oltre · Donne · Aggiornato il 26 mag 2026 · NCT06760507

Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

Emory University/Winship Cancer Institute, Atlanta

In reclutamentoStudio osservazionaleVolontari sani benvenuti

Età 18 e oltre · Donne · Aggiornato il 7 mag 2026 · NCT05877859

Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.